Effects of Aspirin on Kidney Biopsy Bleeding Complications: A Systematic Review and Meta-Analysis (PROSPERO 2021 CRD42021261005).
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
09
06
2022
accepted:
27
01
2023
medline:
29
5
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
Postprocedural bleeding is the main complication of percutaneous kidney biopsy (PKB). Therefore, aspirin is routinely withheld in patients undergoing PKB to reduce the bleeding risk. The authors aimed to examine the association between aspirin use and bleeding during PKB. This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The article search was performed on MEDLINE and Scopus using queries specific to each database. Article inclusion was limited to primary studies. The meta-analysis compared the risk of major bleeding events between the aspirin-exposed versus nonexposed group. Pooled effect estimate was examined using random effects presented as odds ratio with 95% confidence intervals. Heterogeneity was assessed through Cochrane I 2 test statistics. Sensitivity and subgroup analyses were also performed according to kidney type. Ten studies were included in the review and four studies were included in the meta-analysis, reviewing a total of 34,067 PKBs. Definitions for significant aspirin exposure were inconsistent between studies, limiting comparisons. Studies with broader definitions for aspirin exposure mostly showed no correlation between aspirin use and postbiopsy bleeding. Studies with strict definitions for aspirin exposure found an increased risk of hemorrhagic events in the aspirin-exposed group. No significant differences were found between the aspirin-exposed and comparison groups regarding major bleeding events (odds ratio 1.72; 95% confidence interval 0.50 to 5.89, I 2 =84%). High-quality evidence on the effect of aspirin on the bleeding risk is limited. Our meta-analysis did not show a significantly increased risk of major bleeding complications in aspirin-exposed patients. Further studies are needed to define a more comprehensive approach for clinical practice.
Identifiants
pubmed: 36951435
doi: 10.34067/KID.0000000000000091
pii: 02200512-202305000-00020
pmc: PMC10278841
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
700-710Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology.
Références
Hogan JJ, Mocanu M, Berns JS. The native kidney biopsy: update and evidence for best practice. Clin J Am Soc Nephrol. 2016;11(2):354-362. doi: 10.2215/CJN.05750515
doi: 10.2215/CJN.05750515
Stratta P, Canavese C, Marengo M, Mesiano P, Besso L, Quaglia M. Risk management of renal biopsy: 1387 cases over 30 years in a single centre. Eur J Clin Invest. 2007;37(12):954-963. doi: 10.1111/j.1365-2362.2007.01885.x
doi: 10.1111/j.1365-2362.2007.01885.x
Nayak-Rao S. Percutaneous native kidney biopsy in patients receiving antiplatelet agents—is it necessary to stop them routinely? Indian J Nephrol. 2015;25(3):129-132. doi: 10.4103/0971-4065.147374
doi: 10.4103/0971-4065.147374
Hergesell O, Felten H, Andrassy K, Kühn K, Ritz E. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant. 1998;13(4):975-977. doi: 10.1093/ndt/13.4.975
doi: 10.1093/ndt/13.4.975
Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol. 2005;9(1):40-45. doi: 10.1007/s10157-004-0326-7
doi: 10.1007/s10157-004-0326-7
Manno C, Strippoli GF, Arnesano L, Bonifati C, Campobasso N, Gesualdo L. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int. 2004;66(4):1570-1577. doi: 10.1111/j.1523-1755.2004.00922.x
doi: 10.1111/j.1523-1755.2004.00922.x
Shidham GB, Siddiqi N, Beres JA, Logan B, Nagaraja HN, Shidham SG. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton). 2005;10(3):305-310. doi: 10.1111/j.1440-1797.2005.00394.x
doi: 10.1111/j.1440-1797.2005.00394.x
Poggio ED, McClelland RL, Blank KN, Hansen S, Bansal S, Bomback AS. Systematic review and meta-analysis of native kidney biopsy complications. Clin J Am Soc Nephrol. 2020;15(11):1595-1602. doi: 10.2215/CJN.04710420
doi: 10.2215/CJN.04710420
Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation. 2003;76(6):969-973. doi: 10.1097/01.tp.0000082542.99416.11
doi: 10.1097/01.tp.0000082542.99416.11
Korbet SM, Volpini KC, Whittier WL. Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies. Am J Nephrol. 2014;39(2):153-162. doi: 10.1159/000358334
doi: 10.1159/000358334
Morgan TA, Chandran S, Burger IM, Zhang CA, Goldstein RB. Complications of ultrasound-guided renal transplant biopsies. Am J Transplant. 2016;16(4):1298-1305. doi: 10.1111/ajt.13622
doi: 10.1111/ajt.13622
Trajceska L, Severova-Andreevska G, Dzekova-Vidimliski P, Nikolov I, Selim G, Spasovski G. Complications and risks of percutaneous renal biopsy. Open Access Maced J Med Sci. 2019;7(6):992-995. doi: 10.3889/oamjms.2019.226
doi: 10.3889/oamjms.2019.226
Baffour FI, Hickson LJ, Stegall MD, Dean PG, Gunderson TM, Atwell TD. Effects of aspirin therapy on ultrasound-guided renal allograft biopsy bleeding complications. J Vasc Interv Radiol. 2017;28(2):188-194. doi: 10.1016/j.jvir.2016.10.021
doi: 10.1016/j.jvir.2016.10.021
Atwell TD, Smith RL, Hesley GK, Callstrom MR, Schleck CD, Harmsen WS. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol. 2010;194(3):784-789. doi: 10.2214/ajr.08.2122
doi: 10.2214/ajr.08.2122
Mackinnon B, Fraser E, Simpson K, Fox JG, Geddes C. Is it necessary to stop antiplatelet agents before a native renal biopsy? Nephrol Dial Transplant. 2008;23(11):3566-3570. doi: 10.1093/ndt/gfn282
doi: 10.1093/ndt/gfn282
Monahan H, Gunderson T, Greene E, Schmit G, Atwell T, Schmitz J. Risk factors associated with significant bleeding events after ultrasound-guided percutaneous native renal biopsies: a review of 2204 cases. Abdom Radiol (NY). 2019;44(6):2316-2322. doi: 10.1007/s00261-019-01962-z
doi: 10.1007/s00261-019-01962-z
Lees JS, McQuarrie EP, Mordi N, Geddes CC, Fox JG, Mackinnon B. Risk factors for bleeding complications after nephrologist-performed native renal biopsy. Clin Kidney J. 2017;10(4):573-577. doi: 10.1093/ckj/sfx012
doi: 10.1093/ckj/sfx012
Kuiper GJAJ, Christiaans MHL, Mullens MHJM, Ten Cate H, Hamulýak K, Henskens YMC. Routine haemostasis testing before transplanted kidney biopsy: a cohort study. Transplant Int. 2018;31(3):302-312. doi: 10.1111/tri.13090
doi: 10.1111/tri.13090
Potretzke TA, Harvey JA, Gunderson TM, Jensen NM, Schmit GD, McBane RD. Frequency of bleeding complications after percutaneous core needle biopsy and the association with aspirin usage and length of aspirin discontinuation. AJR Am J Roentgenol. 2019;213(1):211-215. doi: 10.2214/AJR.18.20366
doi: 10.2214/AJR.18.20366
Schwarz A, Gwinner W, Hiss M, Radermacher J, Mengel M, Haller H. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant. 2005;5(8):1992-1996. doi: 10.1111/j.1600-6143.2005.00988.x
doi: 10.1111/j.1600-6143.2005.00988.x
Bonani M, Seeger H, Weber N, Lorenzen JM, Wüthrich RP, Kistler AD. Safety of kidney biopsy when performed as an outpatient procedure. Kidney Blood Press Res. 2021;46(3):310-322. doi: 10.1159/000515439
doi: 10.1159/000515439
Wilczek HE. Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation. 1990;50(5):790-797. doi: 10.1097/00007890-199011000-00010
doi: 10.1097/00007890-199011000-00010
Halimi JM, Gatault P, Longuet H, Barbet C, Bisson A, Sautenet B. Major bleeding and risk of death after percutaneous native kidney biopsies: a French Nationwide cohort study. Clin J Am Soc Nephrol. 2020;15(11):1587-1594. doi: 10.2215/CJN.14721219
doi: 10.2215/CJN.14721219
Brachemi S, Bollée G. Renal biopsy practice: what is the gold standard? World J Nephrol. 2014;3(4):287-294. doi: 10.5527/wjn.v3.i4.287
doi: 10.5527/wjn.v3.i4.287
Kumar V, Mitchell MD, Umscheid CA, Berns JS, Hogan JJ. Risk of complications with use of aspirin during renal biopsy: a systematic review. Clin Nephrol. 2018;89(2):67-76. doi: 10.5414/cn109274
doi: 10.5414/cn109274
Lees JS, McQuarrie EP, Mackinnon B. Renal biopsy: it is time for pragmatism and consensus. Clin Kidney J. 2018;11(5):605-609. doi: 10.1093/ckj/sfy075
doi: 10.1093/ckj/sfy075
Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727-736. doi: 10.1016/j.jvir.2012.02.012
doi: 10.1016/j.jvir.2012.02.012
Morais J, Aspirina MSP. 120 anos de história: para além da prevenção cardiovascular. 1 a ed. Heartbrain; 2018.
O'Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019;171(8):596-598. doi: 10.7326/m19-0953
doi: 10.7326/m19-0953
Fang J, George MG, Hong Y, Loustalot F. Use of aspirin for prevention of recurrent atherosclerotic cardiovascular disease among adults—20 States and the District of Columbia, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(27):733-737. PMID:26182190
Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112(2):292-318. doi: 10.1213/ane.0b013e318203f38d
doi: 10.1213/ane.0b013e318203f38d
Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366-1372. doi: 10.1172/jci110576
doi: 10.1172/jci110576
FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676-688. doi: 10.1172/jci110814
doi: 10.1172/jci110814
Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines. Can J Cardiol. 2011;27(3):S1-S59. doi: 10.1016/j.cjca.2010.12.015
doi: 10.1016/j.cjca.2010.12.015
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e326S-e350S. doi: 10.1378/chest.11-2298
doi: 10.1378/chest.11-2298
MacGinley R, Champion De Crespigny PJ, Gutman T, Lopez-Vargas P, Manera K, Menahem S. KHA-CARI Guideline recommendations for renal biopsy. Nephrology (Carlton). 2019;24(12):1205-1213. doi: 10.1111/nep.13662
doi: 10.1111/nep.13662
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. doi: 10.1002/sim.1186
doi: 10.1002/sim.1186
Reschen ME, Mazzella A, Sharples E. A retrospective analysis of the utility and safety of kidney transplant biopsies by nephrology trainees and consultants. Ann Med Surg (Lond). 2018;28:6-10. doi: 10.1016/j.amsu.2018.02.001
doi: 10.1016/j.amsu.2018.02.001
Ori Y, Neuman H, Chagnac A, Siegal A, Tobar A, Itkin M. Using the automated biopsy gun with real-time ultrasound for native renal biopsy. Isr Med Assoc J. 2002;4(9):698-701. PMID:12440234
Andrulli S, Rossini M, Gigliotti G, La Manna G, Feriozzi S, Aucella F. The risks associated with percutaneous native kidney biopsies: a prospective study. Nephrol Dial Transplant. 2022;38(3):655-663. doi: 10.1093/ndt/gfac177
doi: 10.1093/ndt/gfac177
Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med. 2005;257(5):399-414. doi: 10.1111/j.1365-2796.2005.01477.x
doi: 10.1111/j.1365-2796.2005.01477.x
Murphy GJ, Taha R, Windmill DC, Metcalfe M, Nicholson ML. Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Br J Surg. 2002;88(2):261-266. doi: 10.1046/j.1365-2168.2001.01671.x
doi: 10.1046/j.1365-2168.2001.01671.x
Robertson AJ, Nargund V, Gray DW, Morris PJ. Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. Nephrol Dial Transplant. 2000;15(11):1865-1868. doi: 10.1093/ndt/15.11.1865
doi: 10.1093/ndt/15.11.1865
Samama CM, Bastien O, Forestier F, Denninger MH, Isetta C, Juliard JM. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001—summary statement. Can J Anaesth. 2002;49(6):S26-S35.
Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667-2674. doi: 10.1093/eurheartj/ehl334
doi: 10.1093/eurheartj/ehl334
Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217-1220. doi: 10.1001/archneur.62.8.1217
doi: 10.1001/archneur.62.8.1217
Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45(3):456-459. doi: 10.1016/j.jacc.2004.11.041
doi: 10.1016/j.jacc.2004.11.041
Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:157-160. PMID:1825534
Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094. doi: 10.1136/bmj.d4094
doi: 10.1136/bmj.d4094
Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110(16):2361-2367. doi: 10.1161/01.cir.0000145171.89690.b4
doi: 10.1161/01.cir.0000145171.89690.b4